BioStock: NeuroVive presents new strategy for NeuroSTAT
In October, NeuroVive introduced a new strategy for the company – instead of spreading its resources across four indication areas, they chose to focus their work on primary mitochondrial diseases. Of the company’s other three projects, NeuroSTAT against traumatic brain injury (TBI) is the most advanced, and NeuroVive now plans to transfer the rights to develop and commercialise NeuroSTAT to a new company in the United States. CEO Erik Kinnman told BioStock more about this move.
Read the full article and interview at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se